Skip to main content Skip to navigation
We care about your privacy. Read about your rights and how we protect your data. Get Details

Coronavirus Update:What patients and families need to know

Education & Training

  • Fellowship Program, Pediatric Hematology/Oncology, 1995
    Children's National Medical Center
  • Residency Program, Pediatrics, 1992
    Children's National Medical Center
  • MD, 1989
    New York Medical College
  • BS, BS, 1982
    Muhlenberg College

Board Certifications

  • American Board of Pediatrics/Hematology-Oncology

Awards & Recognition

  • Top Doctors No Va Magazine (2020)

National Provider ID: 1023196375


Anne L. Angiolillo, M.D., MS, is the Director of the Leukemia and Lymphoma Program at Children's National Hospital. She specializes in acute lymphoblastic leukemia, non-Hodgkin lymphoma and asparaginase pharmacokinetics.

Dr. Angiolillo has been named a "Top Doctor" by Washingtonian Magazine and has been included in the Best Doctors in America annual database since 2005.

In addition, she recently chaired the Children’s Oncology Group, OG Study, AALL0932 Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy).

Research & Publications

  • Meyer JA, Zhou D, Mason CC, Downie JM, Rodic V, Abromowitch M, Wistinghausen B, Termuhlen AM, Angiolillo AL, Perkins SL, Lones MA, Barnette P, Schiffman JD and Miles RR. Genomic characterization of Pediatric B- Lymphoblastic Lymphoma and B- Lymphoblastic Leukemia Using Formalin Fixed Tissues. Pediatr Blood Cancer, 64(7), 2017.
  • Landier W, Hageman L, Chen Y, Kornegay N, Evans WE, Bostrom BC, Casillas J, Dickens DS, Angiolillo AL, Lew G, Maloney KW, Mascarenhas L, Ritchey AK, Termuhlen AM, Carroll WL, Relling MV, Wong FL, Bhatia S. Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels and Relapse Risk in Children with Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group Study AALL03N1. J Clin Oncol, 35(15):1730-1736, 2017.
  • Reshmil SC, Harvey RC, Roberts KG, Stonerock E, Smith A, Jenkins H, Chen IM, Valentine M, Liu Y, Li Y, Shao Y, Easton J, Payne-Turner D, Gu Z, Tran TH, Nguyen JV, Devidas M, Dai Y, Heerema NA, Carroll AJ 3rd, Raetz EA, Borowitz MJ, Wood BL, Angiolillo AL, Burke MJ, Salzer WL, Zweidler-McKay PA, Rabin KR, Carroll WL, Zhang J, Loh ML, Mullighan CG, Willman CL, Gastier-Foster JM, Hunger SP. Targetable Kinase Gene Fusions in High-Risk B-ALL: a Study From the Children's Oncology Group. Blood, 129(25):3352-3361, 2017.
  • Zheng DJ; Lu X; Schore RJ; Balsamo L; Devidas M; Winick NJ; Raetz EA; Loh ML; Carroll WL; Sung L; Hunger SP; Angiolillo AL; Kadan-Lottick NS. Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children’s Oncology Group AALL0932 Trial. Cancer, 124(3):571-579, 2018.
  • Burke MJ, Devidas M, Maloney K, Angiolillo A, Schore R, Dunsmore K, Larsen E, Mattano LA Jr, Salzer W, Winter SS, Carroll W, Winick NJ, Loh ML, Raetz E, Hunger SP, Bleyer A. Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. Leuk Lymphoma, 59(7):1624-1633, 2018.
  • Schore RJ, Devidas M, Bleyer A, Reaman GH, Winick N, Loh ML, Raetz EA, Carroll WL, Hunger SP, Angiolillo AL. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children’s Oncology Group AALL07P4. Leuk Lymphoma, 60(7):1740-1748, 2019.